Vascular risk factors and Alzheimer disease risk: Epidemiological studies review;Facteurs de risque vasculaire et risque de maladie d'Alzheimer: Revue d'études épidémiologiques

Psychologie et NeuroPsychiatrie du Vieillissement

Volumn 4, Issue 1, 2006, Pages 47-60

  Cowppli Bony, Pascale ^a   Dartigues, Jean François ^a,b   Orgogozo, Jean Marc ^a,b  

^a INSERM   (France)

^b HÔPITAL PELLEGRIN   (France)

Author keywords

Alzheimer's disease; Vascular risk factor

Indexed keywords

APOLIPOPROTEIN E;

ALZHEIMER DISEASE; BLOOD VESSEL INJURY; CEREBROVASCULAR DISEASE; DIABETES MELLITUS; DISEASE ASSOCIATION; HUMAN; HYPERCHOLESTEROLEMIA; HYPERTENSION; INCIDENCE; REVIEW; RISK FACTOR; TOBACCO;

ALZHEIMER DISEASE; APOLIPOPROTEINS E; DIABETES COMPLICATIONS; EPIDEMIOLOGIC STUDIES; GENETIC PREDISPOSITION TO DISEASE; HUMANS; HYPERCHOLESTEROLEMIA; HYPERTENSION; RISK FACTORS; SMOKING;

EID: 33645212089     PISSN: 17601703     EISSN: None     Source Type: Journal    
DOI: None     Document Type: Review

References (122)

1. Boss M. Diagnostic approaches to Alzheimers's disease. Biochim Biophys Acta 2000; 1502: 188-200.
2. World Health Organisation. Mental and neurological disorders, fact sheet n° 265. December 2001. Avalaible at: http://www.who.int/inf-fs/en/fact265. html.Accessed fevrier, 2005.
3. Lobo A, Launer LJ, Fratiglioni L, Andersen K, Di Carlo A, Breteler M, et al. Prevalence of dementia and major subtypes in Europe: a collaborative study of population-based cohorts. Neurology 2000; 54: S4-S9.
4. Institut national de la statistique et des études économiques http://www.insee.fr/fr/ffc/Accessed fevrier, 2005.
5. Ramaroson H, Helmer C, Baberger-Gateau, Letenneur L. Prévalence de la démence et de la maladie d'Alzheimer chez les personnes de 75 ans et plus: données actualisées de la cohorte Paquid. Rev Neurol (Paris) 2002; 159: 405-11.
6. De la Torre J. Alzheimer disease as a vascular disorder. Nosological evidence. Stroke 2002; 33: 1152-62.
7. De la Torre J. Is Alzheimer's disease a neurodegenerative or a vascular disorder? Data, dogma, and dialectics. Lancet Neurol 2004; 3: 184-90.
8. Casserly I, Topol E. Convergence of atherosclerosis and Alzheimer's disease: inflammation, cholesterol, and misfolded proteins. Lancet 2004; 363: 1139-46.
9. Forette F, Seux ML, Staessen JA, Lutgarde T, Babarskiene MR, Babeanu S, et al. The prevention of dementia with antihypertensive treatment: new evidence from the Systolic Hypertension in Europe (Syst-Eur) study. Arch Intern Med 2002; 162: 2046-52.
10. SHEP Cooperative Research Group. Prevention of stroke by antihypertensive drug treatment in older persons with isolated hypertension: final results of the Systolic Hypertension in the Elderly Program (SHEP) trial. JAMA 1991; 265: 3255-64.
11. Lithell H, Hansson L, Skoog I, Elmfeldt D, Hofman A, Olofsson B, et al. The Study on Cognition and Prognosis in the Elderly (SCOPE): principal results of a randomized double-blind intervention trial. J Hypertens 2003; 21: 875-86.
12. Tzourio C, Anderson C, Chapman N. Effects of blood pressure lowering with perindopril and indapamide therapy on dementia and cognitive decline in patients with cerebrovascular disease. Progress Collaborative Group. Arch Intern Med 2003; 163: 1069-75.
13. Feigin V, Ratnasabapathy Y, Anderson C. Does blood pressure lowering treatment prevents dementia or cognitive decline in patients with cardiovascular and cerebrovascular disease? J Neurol Sci 2005; 229-230: 151-5.
14. Hanon O, Seux ML, Lenoir H, Rigaud AS, Forette F. Prevention of dementia and cerebroprotection with antihypertensive drugs. Curr Hypertens Rep 2004; 6: 201-7.
15. Birkenhäger WH, Forette F, Staessen JA. Dementia and antihypertensive treatment. Curr Opin Nephrol Hypertens 2004; 13: 25-30.
16. In't Veld BA, Ruitenberg A, Hofman A, Stricker BH, Breteler MM. Antihypertensive drugs and incidence of dementia: the Rotterdam Study. Neurobiol Aging 2001; 22: 407-12.
17. Qiu C, Winblad B, Fastbom J, Fratiglioni L. Combined effects of APOE genotype, blood pressure, and antihypertensive drug use on incident AD. Neurology 2003; 61: 655-60.
18. Skoog I, Lernfelt B, Landahl S, Palmertz B, Andreasson LA, Nilsson L, et al. 15-year longitudinal study of blood pressure and dementia. Lancet 1996; 347: 1141-5.
19. Qiu C, Von Strauss E, Fastbom J, Winblad B, Fratiglioni L. Low blood pressure and risk of dementia in the Kungsholem project. A 6-year follow-up study. Arch Neurol 2003; 60: 223-8.
20. Verghese J, Lipton RB, Hall CB, Kulansky G, Katz MJ. Low blood pressure and the risk of dementia in very old individuals. Neurology 2003; 61: 1667-72.
21. Morris MC, Scherr PA, Hebert LE, Glynn RJ, Bennett DA, Evans DA. Association of incident Alzheimer's disease and blood pressure measured from 13 years before to 2 years after diagnosis in a large community study. Arch Neurol 2001; 58: 1640-6.
22. Launer LJ, Ross WG, Petrovitch H, Masaki K, Foley D, White LR, et al. Midlife blood pressure and dementia: the Honolulu-Asia aging Study. Neurobiol Aging 2000; 21: 49-55.
23. Benetos A. Pression pulsée, vieillissement artériel et risque cardiovasculaire. La lettre du cardiologue 2001; 350: 24-9.
24. Nawrot TS, Staessen JA, Thijs L, Fagard RH, Tikhonoff V, Wang JG, et al. Should pulse pressure become part of the Framingham risk score? J Hum Hypertens 2004; 18: 279-86.
25. Qiu C, Winblad B, Viitanen M, Fratiglioni L. Pulse pressure and risk of Alzheimer disease in persons aged 75 years and older. Stroke 2003; 34: 594-9.
26. Qiu C, Von Strauss E, Winblad B, Fratiglioni L. Decline in blood pressure over time and risk of dementia. A longitudinal study from the Kungsholem project. Stroke 2004; 35: 1810-5.
27. Petrovitch H, White LR, Izmirilian G, Ross GW, Havlik RJ, Markesbery W, et al. Midlife blood pressure and neuritic plaques, neurofibrillary tangles, and brain weight at death: the HAAS. Neurobiol Aging 2000; 21: 57-62.
28. Sparks DL, Scheff S, Liu H, Landers TM, Coyne CM, Hunsaker JC. Increased incidence of neurofibrillary tangles (NFT) in non-demented individuals with hypertension. J Neurol Sci 1995; 131: 162-9.
29. Heijer TD, Skoog I, Oudkerk M, De Leeuw FE, De Groot JC, Hofman A, et al. Association between blood pressure levels over time and brain in the elderly. Neurobiol Aging 2003; 24: 307-13.
30. Korf ES, White LR, Scheltens P, Launer LJ. Midlife blood pressure and the risk of hippocampal atrophy. The Honolulu Asia Study Aging. Hypertension 2004; 44: 29-34.
31. De Leeuw FE, Richard F, De Groot JC, Van Dujin CM, Hofman A, Van Gijn J, et al. Interaction entre l'hypertension, l'apoE et les lésions cérébrales de la substance blanche. Stroke 2004; 35: 1057-62.
32. Burke VL, Coronado PG, Schmidt CA, Gillepsie KM, Chung HD. Blood pressure regulation in Alzheimer's disease. J Auton Nerv Syst 1994; 48: 65-71.
33. Petitti DB, Crooks VC, Galen Buckwalter J, Chiu V. Blood pressure levels before dementia. Arch Neurol 2005; 62: 112-6.
34. Staessen JA, Wang JG, Thijs L. Cardiovascular protection and blood pressure reduction: a meta-analysis. Lancet 2001; 358: 1305-15.
35. Kjeldsen SE, Dahlof B, Devereux R, Julius S, Aurup P, Edelman J. Effects of losartan on cardiovascular mortality and morbidity in patients with isolated systolic hypertension and ventricular hypertrophy : a Losartan Intervention For Endpoint reduction substudy (LIFE). JAMA 2002; 288: 1491-8.
36. Brands AM, Kessels RP, De Haan EH, Kappelle LJ, Biessels GJ. Cerebral dysfunction in type 1 diabetes: effects of insulin, vascular risk factors and blood-glucose levels. Eur J Pharmacol 2004; 490: 159-68.
37. Arvanitakis Z, Wilson RS, Bienias JL, Evans DA, Bennett DA. Diabetes mellitus and risk of Alzheimer disease and decline in cognitive function. Arch Neurol 2004; 61: 661-6.
38. Awad N, Gagnon M, Messier C. The relationship between impaired glucose tolerance, type 2 diabetes and cognitive function. J Clin Exp Neuropsychol 2004; 26: 1044-80.
39. Fontbonne A, Berr C, Ducimetière P, Alpérovitch A. Changes in cognitive abilities over a 4-year period are unfavorably affected in elderly diabetic subjects. Diabetes Care 2001; 24: 66-70.
40. Wolf-Klein GP, Siverstone FA, Brod MS, Levy A, Foley CJ, Termotto V, et al. Are Alzheimer's patients healthier? J Am Geriatr Soc 1988; 36: 219-24.
41. Janson J, Laedtke T, Parisi JE, O'Brien P, Petersen RC, Butler PC. Increased risk of type 2 diabetes in Alzheimer disease. Diabetes 2004; 53: 474-81.
42. Curb JD, Rodriguez BL, Abbott RD, Petrovitch H, Ross GW, Masaki KH, et al. Longitudinal association of vascular Alzheimer's dementias, diabetes, and glucose tolerance. Neurology 1999; 52: 971-5.
43. Yoshitake T, Kiyohara Y, Kato I, Ohmura T, Iwamoto H, Nakayama K, et al. Incidence and risk factors of vascular dementia and Alzheimer's disease in a defined elderly Japanese population: the Hisayama Study. Neurology 1995; 45: 1161-8.
44. McKnight C, Rockwood K, Await E, McDowell I. Diabetes mellitus and the risk of dementia, Alzheimer's disease and vascular cognitive impairment in the Canadian Study of Health and Aging. Dement Geriatr Disord 2002; 14: 77-83.
45. Luchsinger JA, Tang MX, Stern Y, Shea S, Mayeux R. Diabetes mellitus and risk of Alzheimer's disease and dementia with stroke in a multicentric cohort. Am J Epidemiol 2001; 7: 635-41.
46. Whitmer RA, Sidney S, Selby J, Clairborne J, Yaffe K. Midlife cardiovascular risk factors and risk of dementia in late life. Neurology 2005; 64: 277-81.
47. Ott A, Stolk RP, Van Harkamp F, Pols HA, Hofman A, Breteler MM. Diabetes mellitus and the risk of dementia: the Rotterdam study. Neurology 1999; 53: 1937-42.
48. Peila R, Rodiguez BL, Launer LJ. Type 2 diabetes, ApoE gene and risk for dementia and related pathologies: the Honolulu Asia Study. Diabetes 2002; 51: 1256-62.
49. Leibson CL, Rocca WA, Hanson VA, Cha R, Kokmen E, Obrien PC, et al. Risk of dementia among persons with diabetes mellitus: a population-based study. Am J Epidemiol 1997; 145: 301-5.
50. Xu WL, Qiu CX, Wahlin A, Winblad B, Fratiglioni L. Diabetes mellitus and risk of dementia in the Kungsholmen project. A 6 years follow-up study. Neurology 2004; 63: 1181-6.
51. Borenstein AR, Wu Y, Mortimer JA, Schellenberg GD, McCormick WC, Bowen JD, et al. Developmental and vascular risk factors for Alzheimer's disease. Neurobiol Aging 2005; 26: 325-34.
52. Watson GS, Craft S. Modulation of memory by insulin and glucose: neuropsychological observations in Alzheimer's disease. Eur J Pharmacol 2004; 490: 97-113.
53. Craft S, Watson GS. Insulin and neurodegenerative disease: shared and specific mechanisms. Lancet Neurol 2004; 3: 169-78.
54. Luchsinger JA, Tang MX, Shea S, Mayeux R. Hyperinsulinemia and risk of Alzheimer disease. Neurology 2004; 63: 1187-92.
55. Peila R, Rodriguez BL, White LR, Launer LJ. Fasting insulin and incident dementia in an elderly population of Japanese-American men. Neurology 2004; 63: 228-33.
56. Prince JA, Feuk L, Gu HF, Johanson B, Gatz M, Blennow K, et al. Genetic variation in a haplotype block spanning IDE influences Alzheimer disease. Hum Mut 2003; 22: 363-71.
57. Edland SD, Wavrant-De Vriesé F, Compton D, Smith GE, Ivnik R, Boeve BF, et al. Insulin degrading enzyme (IDE) genetic variants and risk of Alzheimer's disease: evidence of effect modification by apolipoprotein E (APOE). Neurosci Lett 2003; 345: 21-4.
58. Svennerholm L, Gottfries CG. Menbrane lipids, selectively diminished in Alzheimer brains, suggest synapse loss as a primary event in early-onset form and demyelinisation in late-onset form. J Neurochem 1994; 62: 1039-47.
59. Mason RP, Shoemaker WJ, Shajenko L, Chambers TE, Herberte LG. Evidence for changes in the Alzheimer's disease brain cortical menbrane structure mediated by cholesterol. Neurobiol Aging 1992; 13: 413-9.
60. Poirier J. Apolipoprotein E and cholesterol metabolism in the pathogenesis and treatment of Alzheimer's disease. Trends Mol Med 2003;9:94-101.
61. Elias PK, Elias M, D'Agostino R, Sullivan LM, Wolf PA. Serum cholesterol and cognitive performance in the Framingham heart study. Psychosom Med 2005; 67: 24-30.
62. Henderson VW, Guthrie JR, Dennerstein L. Serum lipids and memory in a population based cohort of middle age women. J Neurol Neurosurg Psychiatry 2003; 74: 1530-5.
63. Teunissen CE, De Vente J, Von Bergmann K, Bosma H, Van Boxtel MP, De Brujin C, et al. Serum cholesterol, precursors and metabolites and cognitive performance in an aging population. Neurobiol Aging 2003; 24: 147-55.
64. Lehtonen A, Luutonen S. High-density apolipoprotein cholesterol level of very old people in the diagnosis of dementia. Age Aging 1986; 15: 267-70.
65. Notkola IL, Sulkava R, Pekkanen J, Erkinjunti T, Ehnholm C, Kivinen P, et al. Serum total cholesterol, apolipoprotein E 4 allele, and Alzheimer's disease. Neuroepidemiology 1998; 17: 14-20.
66. Sabbagh M, Zahiri HR, Ceimo J, Cooper K, Gaul W, Connor D, et al. Is there a characteristic lipid profile in Alzheimer's disease? J Alzheimer Dis 2004; 6: 585-9.
67. Kuo YM, Emmerling MR, Bisgaier CL, Essenburg AD, Lampert HC, Drumm D, et al. Elevated low-density lipoprotein in Alzheimer's disease correlates with brain Aβ 1-42 levels. Biochem Biophys Res Commun 1998; 252: 711-5.
68. Lesser G, Kandiah K, Libow LS, Likourezos A, Breuer B, Marin D, et al. Elevated serum total and LDL cholesterol in very old patients with Alzheimer's disease. Dement Geriatr Cogn Disord 2001; 12: 138-45.
69. Letthimaki T, Pirtilla T, Mehta PD, Wisniiewski HM, Frey H, Nikkari T. Apolipoprotein E (ApoE) polymorphism and its influence on ApoE concentrations in the cerebrospinal fluid in Finish patients with Alzheimer's disease. Hum Genet 1995; 95: 39-42.
70. Saunders AM, Strittmatter WJ, Schmechel D, George-Hyslop PH, Periack-Vance MA, Joo SH, et al. Association of apolipoprotein E allele epsilon 4 with late-onset familial and sporadic Alzheimer's disease. Neurology 1993; 43: 1467-72.
71. Schiele F, De Bacquer D, Vincent-Viry M, Beisiegel U, Ehnholm C, Evans A, et al. Apolipoprotein E serum concentration and polymorphism in six European countries: the ApoEurope Project. Atherosclerosis 2000; 152: 475-88.
72. Solfrizzi V, D'Introno A, Colacicco AM, Capurso C, Todarello O, Pellicani V, et al. Circulating biomarkers of cognitive decline and dementia. Clin Chim Acta 2006; 364: 91-112.
73. Tan ZS, Seshadri S, Beiser A, Wilson PW, Kiel DP, Tocco M, et al. Plasma total cholesterol levels as a risk factor for Alzheimer disease, the Framingham Study. Arch Intern Med 2003; 163: 1053-7.
74. Li G, Shofer JB, Kukull WA, Peskind ER, Tsuang DW, Breitner JC, et al. Serum cholesterol and risk of Alzheimer disease. A community-based cohort study. Neurology 2005; 65: 1045-50.
75. Stavra R, Ming-Xin T, Lars B, Mayeux R. ApoE genotype, plasma lipids, lipoproteins and AD in community elderly. Neurology 1999; 53: 517-21.
76. Reitz C, Tang MX, Luchsinger J, Mayeux R. Relation of plasma lipids to Alzheimer's disease and vascular dementia. Arch Neurol 2004; 61: 705-14.
77. Kivipelto M, Helkala EL, Laakso MP, Hanninen T, Hallikainen M, Alhainen K, et al. Apolipoprotein E ε 4 allele, elevated midlife total cholesterol level and high midlife systolic blood pressure are independent risk factors for late-life Alzheimer disease. Ann Intern Med 2002; 137: 149-55.
78. Evans RM, Emsley CL, Gao S, Sahota A, Hall KS, Farlow MR, et al. Serum cholesterol, ApoE genotype, and the risk of Alzheimer's disease: a population-based study of African Americans. Neurology 2000; 54: 240-2.
79. Jarvik GP, Wijsman EM, Kukull WA, Schellenberg GD, Yu C, Larson EB. Interactions of apolipoprotein E genotype, total cholesterol level, age, sex in prediction of Alzheimer's disease: a case-control study. Neurology 1995; 45: 1092-6.
80. Michikawa M. Cholesterol paradox: is high total or low HDL cholesterol level a risk for Alzheimer's disease. J Neurosci Res 2003; 72: 141-6.
81. Morris MC, Evans DA, Bienias JL, Tangney CC, Bennett DA, Aggarwal N, et al. Dietary fats and the risk of incident Alzheimer disease. Arch Neurol 2003; 60: 194-200.
82. Deschamps V, Barberger-Gateau P, Peuchant E, Orgogozo JM. Nutritional factors in cerebral aging and dementia: epidemiological arguments for a role of oxydative stress. Neuroepidemiology 2001; 20: 7-15.
83. Bonarek M, Barberger-Gateau P, Letenneur L, Deschamps V, Iron A, Dubroca B, et al. Relationship between cholesterol, apolipoprotein E polymorphism and dementia: a cross sectional analysis from the Paquid Study. Neuroepidemiology 2000; 19: 141-8.
84. Moroney JT, Tan MX, Berglund L, Small S, Merchant C, Karen B, et al. Low-density lipoprotein cholesterol and the risk of dementia with stroke. Neurology 1999; 282: 254-60.
85. Helbecque N, Amouyel P. Very low density lipoprotein receptor in Alzheimer disease. Microsc Res Tech 2000; 50: 273-7.
86. Refolo LM, Malester B, LaFrancois J, Bryant-Thomas T, Wang R, Tint GS, et al. Hypercholesterolemia accelerates the Alzheimer's amyloid pathology in a transgenic mouse model. Neurobiol Dis 2000; 7: 321-31.
87. Refolo LM, Papolla MA, LaFrancois J, Malester B, Scmidt SD, Thomas-Bryant T, et al. A cholesterol-lowering drug reduces amyloïd pathology in a transgenic mouse model of Alzheimer's disease. Neurobiol Dis 2001; 8: 890-9.
88. Launer LJ, White LR, Petrovitch H, Ross GW, Curb JD. Cholesterol and neuropathologic markers of AD. A population-based autopsy study. Neurology 2001; 57: 1447-52.
89. Delacourte A. Corrélations anatomo-cliniques dans le vieillissement cérébral. In: Michel BF, Verdier JM, eds. Neurodégénérescence et vieillissement céré bral. Paris: Solal, 2004: 41-6.
90. Papolla MA, Bryant-Thomas TK, Herbert D, Pacheco J, Fabra Garcia M, Manjon M, et al. Mild hypercholesterolemia is an early risk factor for the development of Alzheimer's amyloid pathology. Neurology 2003; 61: 199-205.
91. Pitas RE, Boyles JK, Lee SH, Foss D, Mahley RW. Astrocytes synthesize apolipoprotein E and metabolize apolipoproteinE-containing lipoproteins. Biochim Biophys Acta 1987; 91: 148-61.
92. Lutjohann D, Breuer O, Ahlborg G, Nenesmo I, Sidéen A, Diczfalusy U, et al. Cholesterol homeostasis in human brain: evidence for an age-dependant flux of 24S-hydroxycholesterol from the brain to the circulation. Proc Natl Acad Sci USA 1996; 93: 9799-804.
93. Bretillon L, Lutjohann D, Stahle L, Widhe T, Bindl L, Eggertsen G, et al. Plasma levels of 24-hydroxycholesterol reflect the balance between cerebral production and hepatic metabolism and are related to body surface. J Lipid Res 2000; 41: 840-5.
94. Papassotiropoulos A, Lutjohann D, Bagli M, Locatelli S, Jesen F, Rao ML, et al. Plasma 24S-hydroxycholesterol: a peripheral indicator of neuronal degeneration and potential state marker for Alzheimer's disease. Neuroreport 2000; 11: 1959-62.
95. Lutjohaan D, Papassotiropoulos A, Bjorkhem I, Locatelli S, Bagli M, Oehring RD, et al. Plasma 24S-hydroxycholesterol (cerebrosterol) is increased in Alzheimer's disease and vascular demented patients. J Lipid Res 2000; 41: 195-8.
96. Schonknecht P, Lutjohann D, Pantel J, Bardenheuer H, Hartmann T, Von Bergmann K, et al. Cerebrospinal fluid 24S-hydroxycholesterol (cerebrosterol) is increased in patients with Alzheimer's disease in early stages of dementia compared to healthy controls. Neurosci Lett 2002; 324: 83-5.
97. Papassotiropoulos A, Lutjohann D, Bagli M, Locatelli S, Jessen F, Buschfort R, et al. 24S-hydroxycholesterol in cerebrovascular fluid is elevated in early stages of dementia. J Psychiatr Res 2002; 36: 27-32.
98. Kolsch H, Heun R, Kerksiek A, Bergmann KV, Maier W, Lutjohann D. Altered levels of plasma 24-S and 27-hydroxycholesterol in demented patients. Neurosci Lett 2004; 368: 303-8.
99. Papassotiropoulos A, Streffer JR, Tsolaki M, Schmid S, Thal D, Nicosia F, et al. Increased brain β-amyloid load, phosphorylated tau, and risk of Alzheimer disease associated with an intronic CYP46 polymorphism. Arch Neurol 2003; 60: 29-35.
100. Combarros O, Infante J, Liorca J, Berciano J. Genetic association of CYP46 and risk for Alzheimer's disease. Dement Geriatr Cogn Disord 2004; 18: 257-60.
101. Kabbarra A, Payet N, Cottel D, Frigard B, Amouyel P, Lambert JC. Exclusion of CYP46 as candidate genes for Alzheimer's disease in a French population. Neurosci Lett 2004; 363: 139-43.
102. Kolsch H, Lutjohann D, Ludwig M, Schulte A, Ptok U, Jesen F, et al. Polymorphism in the cholesterol 24S-hydroxylase gene is associated with Alzheimer's disease. Mol Psychiatry 2002; 7: 899-902.
103. Wolozin B, Kellman W, Ruosseau P, Celesia GG, Siegel G. Decreased prevalence of Alzheimer disease associated with 3-hydroxy-3-methylglutaryl (HMG)-CoaA reductase inhibitors. Arch Neurol 2000; 57: 1439-43.
104. Jick H, Zornberg GL, Jick SS, Seshadri S, Drachmen DA. Statins and risk of dementia. Lancet 2000; 356: 1627-31.
105. MRC/BHF Heart Protection Study of cholesterol lowering with simvastatin in 20,536 high risk individuals: a randomized, placebo-controlled, double-blind trial. Lancet 2002; 360: 7-22.
106. Shepherd J, Blaw GJ, Murphy MB, Bollen EL, Buckley BM, Cobbe SM, et al. Pravastatin in the elderly individuals at risk of vascular disease (PROSPER). A randomised controlled trial. Lancet 2002; 360: 7-22.
107. Scott HD, Laake K. Statins for the prevention of Alzheimer's disease. Cochrane Database Syst Rev 2001; 4: CD 003160.
108. Michikawa M. The role of cholesterol in pathogenesis of Alzheimer's disease. Mole Neurobiol 2003; 27: 1-12.
109. Wolf H, Hensel A, Arendt T, Kivipelto M, Winblad B, Gertz HJ, et al. Serum lipids and hippocampal volume: the link to Alzheimer's disease? Ann Neurol 2004; 56: 745-8.
110. Murray KN, Abeles N. Nicotine's effect on neural and cognitive functioning in an aging population. Aging Ment Health 2002; 6: 129-38.
111. Newhouse PA, Potter A, Singh A. Effects of nicotinic stimulation on cognitive performance. Curr Opin Pharmacol 2004; 4: 36-46.
112. Ott A, Andersen K, Dewey ME, Letenneur L, Brayne C, Copeland JR, et al. Effect of smoking on global cognitive function in non-demented elderly. Neurology 2004; 62: 920-4.
113. Lee PN. Smoking and Alzheimer disease: a review of the epidemiological evidence. Neuroepidemiology 1994; 13: 131-44.
114. Almeida OP, Hulse GK, Lawrence D, Flicker L. Smoking as a risk factor for Alzheimer's disease: contrasting evidence from a systematic review of case-control and cohort studies. Addiction 2002; 97: 15-28.
115. Tyas SL, Pederson LL, Koval JJ. Is smoking associated with the risk of developing Alzheimer's disease? Results from three Canadian data sets. Ann Epidemiol 2000; 10: 409-16.
116. Letenneur L, Larrieu S, Barberger-Gateau P. Alcohol and tobacco consumption as risk factors of dementia: a review of epidemiological studies. Biomed Psychopharmacol 2004; 58: 95-9.
117. Launer L, Andersen K, Dewey M, Letenneur L, Ott A, Amaducci LA, et al. Rates and risk factors for dementia and Alzheimer's disease: results from Eurodem pooled analyses. Neurology 1999; 52: 78-84.
118. Juan D, Zhou DH, Li J, Wang JY, Gao C, Chen M. A 2-years follow-up study of cigarette smoking and risk of dementia. Eur J Neurol 2004; 4: 277-82.
119. Ott A, Slooter AJ, Hoffman AJ, Van Harskamp F, Witteman JCM, Van Broeckhoven C, et al. Smoking and risk of dementia and Alzheimer's disease in a population-based cohort study: the Rotterdam study. Lancet 1998; 351: 1840-3.
120. Merchant C, Tang MX, Albert S, Manly J, Stern Y, Mayeux R. The influence of smoking on the risk of Alzheimer's disease. Neurology 1999; 52: 1408-12.
121. Zanardi A, Leo G, Biagini G, Zoli M. Nicotine and neurodegeneration in ageing. Toxicol Lett 2002; 127: 207-15.
122. Kukull WA. The association between smoking and Alzheimer's disease: effects of study design and bias. Biol Psychiatry 2001; 49: 194-9.